What it sells
Menten AI designs peptide and protein therapeutics using quantum…
Business model breakdown
Buyer: who owns the budget?
Pharma and biotech discovery/R&D leads (strategic partnerships; claims top-10 pharma partners).
Trigger: what makes them buy now?
UnverifiedHard or undruggable targets, especially protein-protein interfaces where screening fails.
Workflow: what inputs become what output?
MAUD 1.0 designs peptide macrocycles de novo using generative AI, physics-based models and quantum simulation, then optimizes potency, permeability and oral bioavailability.
Economics: what it saves and how it charges
UnverifiedPartnership/discovery-collaboration model (terms not published); claims >90% hit rate, nM potency.
Distribution: how it reaches customers
Business-development led: "Partner with Us" contact form.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.